A fluorine-containing cyclic compound is represented by the formula 1:
1
wherein each of R
1
, R
2
and R
3
independently represents a hydrogen, alkyl group, fluorine, fluoroalkyl group or hexafluorocarbinol group,
wherein at least one of the hexafluorocarbinol groups may partly or totally be protected with a protecting group, and
wherein the protecting group is (a) a straight-chain, branched or cyclic hydrocarbon group having a carbon atom number of 1-25 or (b) an aromatic hydrocarbon group and optionally contains a fluorine atom, oxygen atom, nitrogen atom or carbonyl bond.
Biologically Active Trifluoromethyl‐Substituted Metallocene Triazoles: Characterization, Electrochemistry, Lipophilicity, and Cytotoxicity
作者:Marcus Maschke、Max Lieb、Nils Metzler‐Nolte
DOI:10.1002/ejic.201200798
日期:2012.12
of four different trifluoromethylated metallocenetriazoles and their biological evaluation (M = Fe and Ru). The cytotoxicity of all compounds was evaluated using MCF-7, HT-29, PT-45 and GM5657 cells and IC50 values as low as 33 μM were found. It was shown that the metallocene moiety is crucial for the cytotoxic effect. The electrochemical behavior of triazoles 3–6 was investigated by cyclic voltammetry
我们报告了四种不同三氟甲基化茂金属三唑的简便合成及其生物学评价(M = Fe 和 Ru)。使用 MCF-7、HT-29、PT-45 和 GM5657 细胞评估了所有化合物的细胞毒性,发现 IC50 值低至 33 μM。结果表明,茂金属部分对细胞毒性作用至关重要。通过循环伏安法研究了三唑 3-6 的电化学行为。这些电化学测量表明,所有三唑都比二茂铁更不容易氧化。此外,通过 RP-HPLC 测定的 Log P 表明氟化衍生物的亲脂性增加,Log P 值高达 3.8。此外,通过将三唑 7 与氨基酸 L-亮氨酸偶联可以实现成功的生物偶联。
Malonyl-coa decarboxylase inhibitors useful as metabolic modulators
申请人:——
公开号:US20040082576A1
公开(公告)日:2004-04-29
The present invention relates to novel compounds (I), their prodrugs, and the pharmaceutically acceptable salts as well as pharmaceutical compositions containing such compounds useful in treating certain metabolic diseases and diseases modulated by the inhibition of the enzyme malonyl-coenzyme A decarboxylase (malonyl-CoA decarboxylase, MCD). In particular, the invention relates to compounds and compositions and the methods for the prophylaxis, management and treatment of cardiovascular diseases, diabetes, acidosis, cancers, and obesity through the inhibition of malonyl-coenzyme A decarboxylase.
Malonyl-CoA Decarboxylase Inhibitors Useful as Metabolic Modulators
申请人:Arrhenius Thomas
公开号:US20100016259A1
公开(公告)日:2010-01-21
The present invention relates to novel compounds (I), their prodrugs, and the pharmaceutically acceptable salts as well as pharmaceutical compositions containing such compounds useful in treating certain metabolic diseases and diseases modulated by the inhibition of the enzyme malonyl-coenzyme A decarboxylase (malonyl-CoA decarboxylase, MCD). In particular, the invention relates to compounds and compositions and the methods for the prophylaxis, management and treatment of cardiovascular diseases, diabetes, acidosis, cancers, and obesity through the inhibition of malonyl-coenzyme A decarboxylase.